Inactivated poliovirus vaccine: past and present experience
- PMID: 8817819
- DOI: 10.1016/0264-410x(95)00211-i
Inactivated poliovirus vaccine: past and present experience
Abstract
Many countries have made use of inactivated poliovirus vaccine (IPV) in their national poliovirus control programs since 1955. Until 1961 IPV was the only vaccine available for the control of poliovirus, but subsequently many countries opted to use the Sabin attenuated poliovirus vaccine (OPV), which was perceived as more effective in preventing intestinal infection and in ensuring community protection by spreading to unvaccinated contacts of vaccinees. Nevertheless, IPV has remained the vaccine of choice in several countries, where experience has shown that it represents a safe and effective option for disease control. IPV limits subsequent infection of the pharynx and intestine in vaccinees, and is able to control circulation of poliovirus in a vaccinated population, providing effective community protection. Furthermore IPV contains only killed virus and cannot cause vaccine-associated paralytic poliomyelitis as OPV sometimes does. This paper reviews the history of the use of IPV, with emphasis on its efficacy and its ability to safely protect communities in which it is used. As the incidence of poliomyelitis declines new control strategies should take account of the knowledge of the use of poliovirus vaccines acquired since 1955.
Similar articles
-
Anomalous observations on IPV and OPV vaccination.Dev Biol (Basel). 2001;105:197-208. Dev Biol (Basel). 2001. PMID: 11763328
-
World wide experience with inactivated poliovirus vaccine.Vaccine. 2008 Sep 15;26(39):4978-83. doi: 10.1016/j.vaccine.2008.07.026. Epub 2008 Aug 3. Vaccine. 2008. PMID: 18680777 Review.
-
A developing country perspective on vaccine-associated paralytic poliomyelitis.Bull World Health Organ. 2004 Jan;82(1):53-7; discussion 57-8. Epub 2004 Feb 26. Bull World Health Organ. 2004. PMID: 15106301 Free PMC article.
-
Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries.Wkly Epidemiol Rec. 2003 Jul 11;78(28):241-50. Wkly Epidemiol Rec. 2003. PMID: 15571166 English, French.
-
Poliovirus vaccine options.Am Fam Physician. 1999 Jan 1;59(1):113-8, 125-6. Am Fam Physician. 1999. PMID: 9917578 Review.
Cited by
-
Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol.Front Cell Infect Microbiol. 2024 Apr 4;14:1371695. doi: 10.3389/fcimb.2024.1371695. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38638823 Free PMC article.
-
Recent and advanced nano-technological strategies for COVID-19 vaccine development.Methods Microbiol. 2022;50:151-188. doi: 10.1016/bs.mim.2022.03.001. Epub 2022 Apr 18. Methods Microbiol. 2022. PMID: 38620863 Free PMC article.
-
Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination.Curr Microbiol. 2023 Oct 20;80(12):377. doi: 10.1007/s00284-023-03432-8. Curr Microbiol. 2023. PMID: 37861721
-
Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.Viruses. 2023 Aug 28;15(9):1826. doi: 10.3390/v15091826. Viruses. 2023. PMID: 37766233 Free PMC article. Review.
-
COVID-19 immunity and vaccines: what a pharmacist needs to know.Asian Biomed (Res Rev News). 2021 Apr 30;15(2):51-67. doi: 10.2478/abm-2021-0008. eCollection 2021 Apr. Asian Biomed (Res Rev News). 2021. PMID: 37551403 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous